International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 13 Issue 1, January - March, Pages:18-28

Association Of Serum Uric Acid With Insulin Resistance

Ankur Sony , Kavitarati Dharwadkar , Shrikant chandrakar , Ashish Jain and Archana Sharma pandey

Overweight, obesity which further leads to insulin resistance represents a rapidly growing threat to the health of populations in an increasing number of countries. Obesity leads to Insulin resistance (IR) which is further established by genetic and environmental factors. Insulin resistance leads to impaired glucose tolerance and which further plays an important pathophysiological role in the development of diabetes. Insulin resistance leads to many complications like severe high blood pressure, severe low blood pressure, cardiac diseases, stroke, renal diseases, retinopathies, cancer, Alzheimer’s disease, and other neurological problems. So, it is very important for clinicians to identify obesity and early interference to stop insulin resistance to prevent obese individuals to become diabetic. So, we performed Hospital based case control study and included 75 cases of non-obese and 75 cases of obese pre-diabetic individuals of age between 20-50 years and after performing relevant statistical analysis of obtained data we found that obese individuals have high insulin resistance and there is strong significant association between uric acid and BMI, uric acid and WHR, uric acid and insulin levels, uric acid and HOMA IR (Insulin resistance) in obese prediabetic patients. Our study showed that the mean serum uric acid value in males was 7.44 ± 0.29 while in females it was 7.35 ± 0.43, and the difference was statistically significant in this study. Thus, uric acid could serve as a good & cost-effective marker to predict insulin resistance association of uric acid with BMI, WHR which leads to insulin resistance in people with obesity.

Keywords: Body mass index (BMI), Insulin resistance, Waist hip ratio (WHR), Pre-Diabetic, Uric acid, Insulin, Obesity.
Full HTML:



  1. Diabetes Australia. Diabetes globally [internet]. Canberra, ACT: Diabetes Australia; 2012 [cited:2012: Nov:5]. Available from:
  2. World Health Organization. Physical Status: use and interpretation of anthropometry. Report of WHO. Geneva: Expert Committee. WHO.
  3. Peter GK, Lorraine A. Obesity, non-insulin dependent diabetes mellitus and metabolic syndrome. Br Med Bull. 1997;53(2):322-40.
  4. World Health Organization. Diet, nutrition and the prevention of chronic diseases. Report of a joint WHO/FAO. Geneva: Expert Consultation WHO; 2003.
  5. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO Consultation 2000, Technical Report Series. 894. Geneva: WHO.
  6. World Health Organization. Prevention of diabetes mellitus. Technical Report Series No. 84. Geneva: WHO.
  7. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739-42. Doi: 10.1111/j.1523-1755.2005.00273.x, PMID 15840020.
  8. Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1): E1-5. Doi: 10.1152/ajpendo.1995.268.1.E1, PMID 7840165.
  9. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism. 1981;30(6):616-34. Doi: 10.1016/0026-0495(81)90142-6, PMID 6262603.
  10. Liberopoulos EN, Miltiadous GA, Elisaf MS. Alcohol intake, serum uric acid concentrations, and risk of gout. Lancet. 2004;364(9430):246-7; author reply 247. Doi: 10.1016/S0140-6736(04)16669-5, PMID 15262098.
  11. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25(10):1790-4. Doi: 10.2337/diacare.25.10.1790, PMID 12351479.
  12. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928-33. Doi: 10.1253/circj.69.928, PMID 16041161.
  13. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55(10):1293-301. Doi: 10.1016/j.metabol.2006.05.013, PMID 16979398.
  14. Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, Nakayama A, Matsuo H, Sanada H, Jose PA, Miwa Y, Hisaoka T, Isonuma H. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens (Greenwich). 2016;18(1):53-9. Doi: 10.1111/jch.12627, PMID 26212524.
  15. Wei F, Sun N, Cai C, Feng S, Tian J, Shi W, Xu W, Wang Y, Yang X, Li WD. Associations between serum uric acid and the incidence of hypertension: a Chinese senior dynamic cohort study. J Transl Med. 2016;14(1):110.Doi:10.1186/s12967-016-0866-0,PMID 27129957.
  16. Li LX, Dong XH, Li MF, Zhang R, Li TT, Shen J, Shen J, Bao YQ, Jia WP. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482-90; discussion 490. Doi: 10.1097/HJH.0000000000000417, PMID 25405332.
  17. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176(2):108-16±16. Doi: 10.1093/aje/kws002, PMID 22753829.
  18. Meisinger C, Döring A, Stöckl D, Thorand B, Kowall B, Rathmann W. Uric acid is more strongly associated with impaired glucose regulation in women than in men from the general population: the KORA F4- Study. PLOS ONE. 2012;7(5): e37180. Doi: 10.1371/journal.pone.0037180, PMID 22615932.
  19. Kawamoto R, Tabara Y, Kohara K, Kusunoki T, Abe M, Miki T. Serum uric acid is more strongly associated with impaired fasting glucose in women than in men from a community-dwelling population. PLOS ONE. 2013;8(6): e65886. Doi: 10.1371/journal.pone.0065886, PMID 23785457.
  20. Liu Y, Jin C, Xing A, Liu X, Chen S, Li D, Feng P, Liu J, Li Z, Wu S. Serum uric acid levels and the risk of impaired fasting glucose: a prospective study in adults of north China. PLOS ONE. 2013;8(12): e84712. Doi: 10.1371/journal.pone.0084712, PMID 24376838.
  21. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013; 4:37. Doi: 10.3389/fendo.2013.00037, PMID 23542897.
  22. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340(8825):925-9±9. Doi: 10.1016/0140-6736(92)92814-v, PMID 1357346.
  23. Tang W, Fu Q, Zhang Q, Sun M, Gao Y, Liu X, Qian L, Shan S, Yang T. The association between serum uric acid and residual beta -cell function in type 2 diabetes. J Diabetes Res. 2014; 2014:709691. Doi: 10.1155/2014/709691, PMID 24971368.
  24. Marques-Vidal P, Dias CM. Trends in overweight and obesity in Portugal, The National Health survey 1995-96 and 1998-99. Obes Res. 2005;13(7):1141-5. Doi: 10.1038/oby.2005.135, PMID 16076982.
  25. Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, Johnson RJ, Nakagawa T. Thiazide diuretics exacerbate fructose induced metabolic syndrome. J Am Soc Nephrol. 2007;18(10):2724-31. Doi: 10.1681/ASN.2007040416, PMID 17855639.
  26. Verma NP, Mehta SP, Madhu S, Mather HM, Keen H. Prevalence of known diabetes in an urban Indian environment: the Darya Ganj Diabetes Survey. Br Med J (Clin Res Ed). 1986;293(6544):423-4. Doi: 10.1136/bmj.293.6544.423, PMID 3091141.
  27. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract. 2003;61(1):69-76. Doi: 10.1016/s0168-8227(03)00085-8, PMID 12849925.
  28. Gupta R, Sarna M, Thanvi J, Rastogi P, Kaul V, Gupta VP. High prevalence of multiple coronary risk factors in Punjabi Bhatia Community: Jaipur Heart Watch-3. Indian Heart J. 2004;56(6):646-52. PMID 15751521.
  29. Omar MA, Seedat MA, Dyer RB, Rajput MC, Motala AA, Joubert SM. The prevalence of diabetes in a large group of South African Indians. S Afr Med J. 1985;67(23):924-6. PMID 4002074.
  30. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes related cardiovascular comorbidities in the U.S. 2000-2002. Diabetes Care. 2005;28(7):1599-603. doi: 10.2337/diacare.28.7.1599, PMID 15983307.
  31. Panagiotakos DB, Pitsavos C, Chrysohoou C, Risvas G, Kontogianni MD, Zampelas A, Stefanadis C. Epidemiology of overweight and obesity in Greek adult population: the ATTIKA study. Obes Res. 2004;12(12):1914-20.Doi:10.1038/oby.2004.239, PMID 15687390.
  32. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with Benzbromarone in patients with heart failure: a double-blind placebo controlled crossover preliminary study. Circ Heart Fail. 2010;3(1):73-81. Doi:10.1161/CIRCHEARTFAILURE.109.868604, PMID 19933411.
  33. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan A, Kalay N. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press.2011;20(3):182.Doi:10.3109/08037051.2010.538977,PMID21133824




[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions